Leerink's Outperform rating and $30 target give KZIA a favorable new outside assessment. It is an analyst's view, not evidence of changed trial results or sales, so the support is limited.
The new rating adds a favorable outside view of Kazia's prospects. The $30 target supports that reading, but it is an analyst opinion, not a report of changed trial results or sales.
Follow Kazia Therapeutics Limited (KZIA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KZIA